Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

August 7, 2026
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

July 13, 2026July 13, 2026

Why Do We Age? The Biology Of Ageing Explained

1
October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

2
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

3
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

4
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

5
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • Are COVID-19 patients diagnosed with Down Syndrome prone to severe diseases?

The Critical role of UGP2 - Pancreatic Ductal Adenocarcinoma Treatment

NICED Influenza Project Recruitment For Life Science | Applications Invited

Are COVID-19 patients diagnosed with Down Syndrome prone to severe diseases?
  • BiotechToday
  • World

Are COVID-19 patients diagnosed with Down Syndrome prone to severe diseases?

bioxone October 18, 2020October 18, 2020

Sayak Banerjee, Amity University Kolkata

Down syndrome (DS), also known as trisomy 21 is the most persistent aneuploidy characterized by a genetic disorder caused due to the triplication of the 21st human chromosome. This syndrome is particularly associated with the development of congenital heart disease, sleep apnoea, obesity, diabetes, premature ageing, and higher sensitivity to upper respiratory tract infections. Each of these is probable to make people with DS, more susceptible to severe SARS-CoV-2, which has left no country unaffected. Due to their dysregulation of the immune system, consequences like cytokine storm may arise which can lead to acute respiratory distress syndrome (ARDS) and cardiac anomalies.

To study the disease characteristics in these patients, the researchers enlisted hospitalized patients admitted at Mount Sinai and Columbia University health systems with a diagnosis of COVID-19 who already had a DS diagnosis in their medical record. They were compared to a control group consisting of five patients without DS, hospitalized with COVID-19. The control group had the usual conditions of hypertension, type 2 diabetes mellitus, and lung disease. On a contrary, the DS group predominated with the co-occurring conditions of not only hypothyroidism and diabetes, but also neurological disorders of dementia and epilepsy. 

Hypothyroidism and dementia were notably higher in the DS rather than the control group, out of which an escalated COVID-19 mortality risk was seen in dementia. WBC count was lower in patients with DS than in controls accompanying an increased inflammation due to hypersecretion of cytokines. As a result, 10 out of 12 patients with DS had an increased prevalence of sepsis and mechanical ventilation, proving to be another marker of severe disease in DS. The researchers found that there are a drastic disease progression and higher threats of acute lung injury and ARDS in DS groups contrasted to controls, which could lead to high mortality rates among them. 

They concluded that due to intellectual disability and immune impairments, patients with DS are more prone to severe COVID-19 and the healthcare systems should focus on their treatment and prevention with essential care.

Also read: The Critical role of UGP2 – Pancreatic Ductal Adenocarcinoma Treatment

Source: Malle, L., Gao, C., Hur, C. et al. Individuals with Down syndrome hospitalized with COVID-19 have more severe disease. Genet Med (2020). https://doi.org/10.1038/s41436-020-01004-w

  • Why Do We Age? The Biology Of Ageing Explained
  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related

Tagged aneuploidy ARDS cardiac chromosome congenital COVID-19 cytokine cytokine storm Diabetes Mellitus disease progression Down syndrome Genetic Disorder heart disease Hypertension hypothyroidism immune system inflammation lung disease mortality neurological disorder SARS-CoV-2 syndrome trisomy 21 type 2 diabetes mellitus

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • Job and Internship
  • Signaling Pathway

NICED Influenza Project Recruitment For Life Science | Applications Invited

bioxone October 18, 2020

-Shristi Sharma, Team bioXone NICED SRF Job – Life Science Senior Research Fellow. ICMR-National Institute of Cholera & Enteric Diseases recruiting for Senior Research Fellow position for MSc Life Sciences candidates. Research positions for msc/bsc candidates at NICED, details given below: No. 26/Influenza Surveillance INSPIRE II/2020 Title of Job: Senior Research Fellow (Non-Medical) No. of […]

Related Post

  • BiotechToday
  • India
  • World

AstraZeneca: Late-stage trial of Covid-19 antibody medicine to start soon

bioxone October 12, 2020October 12, 2020

Prama Ghosh, Amity University Kolkata After the recovery of President Donald Trump from Covid-19 using a similar therapy as of the antibody medicine from AstraZeneca Plc, the company has started its late-stage trials for the same against COVID-19. The medicine will undergo two trials on more than 60000 people starting soon. Astra has also planned […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Invisible cancer risk in talc-based cosmetics

bioxone December 4, 2020December 4, 2020

Devyani Goswami, Amity University Kolkata More than 60% of cosmetics products are made up of talc to enhance the quality of the product. A two years (2018-2020) study concluded that every talc-based cosmetics products have a little amount of asbestos in them which can cause cancer, as many complaints were made stating women suffering from […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

World Bladder Cancer Awareness Month – May 2021

bioxone May 15, 2021May 15, 2021

Anuska Sen, Team BioXone “Have you ever heard about bladder cancer?” That’s the question this year’s theme of World Bladder Cancer Awareness Month asks us. It is believed that this one question if asked to people can make many of us “Bladder Cancer Aware”. The World Bladder Cancer Awareness Month is celebrated in May each […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Breaking News

Why Do We Age? The Biology Of Ageing Explained

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy